This is the first book that discusses the subjects of diagnosis, therapy, therapy assessment, and prognosis of lung and prostate cancer in one single volume.

Cancer killed 6.7 million people around the world in 2002, and this figure is expected to rise to 10.1 million in 2020. Lung cancer has been the most common cancer in the world since 1985, and by 2002 there were 1.35 million new cases, representing 12.5% of all new cancers. It was also the most common cause of death from cancer, with 1.18 million deaths (17.6% of the world total). Lung cancer remains a highly lethal disease. After diagnosis, survival at 5 years in the United States is 15%.

This second volume in the series Methods of Cancer Diagnosis, Therapy and Prognosis presents a comprehensive treatise on all aspects of Lung and Prostate cancer, including diagnosis, treatments and prognosis. Scientists and Clinicians have contributed state of the art chapters on their respective areas of expertise providing the reader a whole field view of lung and prostate cancer management.

This fully illustrated volume Discusses diagnosis using molecular genetics, various imaging modalities, tumor markers and tumor gene therapy Discusses treatments such as chemotherapy, radiation, chemoradiation, hormonal therapy, immunotherapy, and surgery; and prognosis Highlights both primary and secondary cancers, and explains the risk of cancer survivors developing other cancers. Attempts to translate molecular genetics into clinical practice. Evidence-based therapy is included. Discusses the role of histology and immunohistochemistry in differentiating between pleuropulmonary desmoid tumors and solid fibroustumors. Discusses cancer stem cells, mutations, cancer vaccines, and personalized cancer medicine. Professor Hayat has summarized the problems associated with the complexities of research publications and has been successful in editinga must-read volume for oncologists, cancer researchers, medical teachers and students of cancer biology.

Zusammenfassung
Cancer is the leading cause of death, in the number of older cancer patients is after cardiovascular diseases, in the expected. Approximately, 77% of all types United States. A total of ? 1,399,790 new of cancers are diagnosed in persons of 55 cancer cases and ? 564,830 deaths were years and older. It was estimated that o- reported in the year 2006 in the country. third of the 559,650 cancer deaths in 2007 Approximately, one in every two men and in the United States were related to ov- one in every three women in the country weight or obesity, physical inactivity, and will have some type of cancer during nutrition, and thus could also be prevented their lifetime. Healthcare costs exceed (Am. Cancer Society, 2007). However, 1. 7 trillion dollars per year in the United in developed countries, including United States, which is ? 15% of the country's States, the average person of 65 years can gross domestic product. expect to live another 15 years in a fairly Tobacco use is the most serious prevent- good health. Persons of 75 or 85 years old able cause of cancer. Tobacco use causes have an average expectancy of 10 and 6 cancer of the lung, throat, mouth, pancreas, years, respectively. urinary bladder, stomach, liver, kidney, and During the last three decades, intensive other types. Passive smoking causes lung clinical research has resulted in reduced cancer.

Inhalt
General Methods and Overviews.- Metabolic Transformations of Malignant Cells: An Overview.- Detection of Recurrent Cancer by Radiological Imaging.- Tumor Gene Therapy: Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy.- Assessment of Gene Transfer: Magnetic Resonance Imaging and Nuclear Medicine Techniques.- Role of TP53 Mutations in Cancer (An Overview).- Personalized Medicine for Cancer.- Radiation Doses to Patients Using Computed Radiography, Direct Digital Radiography, and Screen-Film Radiography.- Cancer Vaccines and Immune Monitoring (An Overview).- New Insights into the Role of Infection,Immunity and Apoptosis in the Genesis of the Cancer Stem Cell.- Successful Cancer Treatment: Eradication of Cancer Stem Cells.- Overexposure of Patients to Ionizing Radiation: An Overview.- Lung Cancer.- Lung Carcinoma.- Extra-Pulmonary Small Cell Cancer: Diagnosis, Treatment, and Prognosis.- Magnetic Resonance Imaging of the Lung: Automated Segmentation Methods.- Peripheral Lung Lesions: Diagnosis Using Transcutaneous Contrast-Enhanced Sonography.- Small Pulmonary Nodules: Detection Using Multidetector-Row Computed Tomography.- Secondary Primary Cancer Following Chemoradiation for Non-Small-Cell Lung Cancer.- Advanced Non-Small Cell Lung Cancer: Second-Line Treatment with Docetaxel.- Non-Small Cell Lung Cancer with Brain Metastases: Platinum-Based Chemotherapy.- Non-Small Cell Lung Carcinoma: EGFR Gene Mutations and Response to Gefitinib.- Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib.- Prognostic Significance of [18F]-Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Pathological Stage I Lung Adenocarcinoma.- Non-Small Cell Lung Cancer: Prognosis Using the TNM Staging System.- Differentiation Between Malignant andBenign Pleural Effusions: Methylation Specific Polymerase Chain Reaction Analysis.- Pathological Distinction of Pulmonary Large Cell Neuroendocrine Carcinoma from Small-Cell Lung Carcinoma Using Immunohistochemistry.- Differentiation Between Pleuropulmonary Desmoid Tumors and Solitary Fibrous Tumors: Role of Histology and Immunohistochemistry.- Non-Small Cell Lung Cancer with Brain Metastasis: Role of Epidermal Growth Factor Receptor Gene Mutation.- Prostate Cancer.- Prostate Carcinoma.- The Role of Intermediary Metabolism and Molecular Genetics in Prostate Cancer.- Array-Based Comparative Genomic Hybridization in Prostate Cancer: Research and Clinical Applications.- Prostate Cancer: Role of Vav3 Overexpression in Development and Progression.- Prostate Cancer: Detection and Monitoring Using Mitochondrial Mutations as a Biomarker.- Prognostic Markers in Prostatic Carcinoma.- Prostate Cancer: Detection of Free Tumor-Specific DNA in Blood and Bone Marrow.- Prostate Carcinoma: Evaluation Using Transrectal Sonography.- Prostate Cancer: 16?-[18F] Fluoro-5?-Dihydrotesterone (FDHT) Whole-Body Positron Emission Tomography.- Effects of Standard Treatments on the Immune Response to Prostate Cancer.- Vinorelbine, Doxorubicin, and Prednisone in Hormone Refractory Prostate Cancer.- Locally Advanced Prostate Cancer Biochemical Recurrence after Radiotherapy: Use of Cyclic Androgen Withdrawal Therapy.